Financial Analysis: Alpha Tau Medical (NASDAQ:DRTS) versus Nyxoah (NASDAQ:NYXH)

Nyxoah (NASDAQ:NYXH) and Alpha Tau Medical (NASDAQ:DRTS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Insider & Institutional Ownership

2.7% of Alpha Tau Medical shares are owned by institutional investors. 17.1% of Nyxoah shares are owned by insiders. Comparatively, 39.5% of Alpha Tau Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Nyxoah and Alpha Tau Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nyxoah	-1,043.93%	-51.68%	-40.11%
Alpha Tau Medical	N/A	-38.62%	-29.89%

Analyst Ratings

This is a breakdown of current ratings and target prices for Nyxoah and Alpha Tau Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	0	0	5	0	3.00
Alpha Tau Medical	0	0	3	0	3.00

Nyxoah currently has a consensus price target of $17.00, suggesting a potential upside of 112.50%. Alpha Tau Medical has a consensus price target of $8.00, suggesting a potential upside of 244.83%. Given Alpha Tau Medical’s higher possible upside, analysts clearly believe Alpha Tau Medical is more favorable than Nyxoah.

Volatility & Risk

Nyxoah has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, Alpha Tau Medical has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Valuation & Earnings

This table compares Nyxoah and Alpha Tau Medical”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$5.08 million	39.26	-$46.77 million	($1.87)	-4.28
Alpha Tau Medical	N/A	N/A	-$29.16 million	($0.43)	-5.40

Alpha Tau Medical has lower revenue, but higher earnings than Nyxoah. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Summary

Alpha Tau Medical beats Nyxoah on 8 of the 12 factors compared between the two stocks.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.